Quintiles expands kidney disease trial offering with DaVita deal

Quintiles ($Q) has teamed up with kidney care specialist DaVita Clinical Research in a deal designed to help shore up offerings in renal disease clinical trials.

DaVita Clinical Research, part of DaVita Healthcare Partners, is a major healthcare player, working with more than one million patients--patients that can be sought for clinical trials.

In a joint statement, both companies point out the studies for patients with kidney problems are becoming more complex in terms of how they are put together, while biopharmas are calling for broader patient populations.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

In this collab, financial details of which were not disclosed, the two companies said they will come together in order to: “Provide capabilities and solutions for overcoming these challenges to deliver end-to-end support for renal disease clinical trials.”

They added in a statement: “By leveraging Quintiles’ protocol modeling and feasibility, in combination with DaVita’s extensive patient understanding, biopharmaceutical customers will be able to take advantage of the combined assets of both companies to progress their clinical programs.”

Amy Young, VP and general manager of DaVita Clinical Research, said: “This alliance allows novel approaches to clinical development and clinical trial execution specifically in site identification, participant enrollment and study design. We are excited about the opportunities this affords our organizations to provide innovative solutions to the biopharmaceutical industry and the participants we serve.”

- check out the release

Related Articles:
Quintiles, IMS Health unveil surprise megamerger
Quintiles bets on a big 2016 as revenue rolls in


Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.